LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Groundbreaking Genomics Method to Improve Early Detection of Genetic Diseases

By LabMedica International staff writers
Posted on 02 Dec 2024
Print article
Image: The groundbreaking genomics method has the potential to uncover insights previously missed (Photo courtesy of 123RF)
Image: The groundbreaking genomics method has the potential to uncover insights previously missed (Photo courtesy of 123RF)

Researchers using next-generation sequencing are uncovering valuable insights from the non-coding segments of human DNA, which were once considered "junk DNA." These segments, called non-coding RNAs, hold critical information on the presence of diseases. In a new approach, scientists are working to adapt laboratory equipment initially designed to analyze only mRNA, the coding parts of genetic material, and also examine the non-coding regions of DNA. This innovative genomics technique could reveal the genetic mechanisms behind both human health and diseases, offering a potential method for early detection of conditions like cancer and dementia. The research, published in Genome Biology, proposes a novel approach to exploring the root causes of various diseases.

Over the past two decades, researchers have used advanced tools to analyze non-coding RNAs and identify the 3% of sequences that are coded. As part of the Canadian Epitranscriptomics Project, scientists at the University of Manitoba (Winnipeg, Canada) are leveraging this technology to create the "Epitranscriptome Atlas," which aims to map the remaining 97% of the human genome. This effort will enhance our understanding of how alterations in non-coding RNAs contribute to disease.

“My lab applies what we call next-generation sequencing and bioinformatics to magnify the impact of recent advances in AI algorithms,” said Dr. Athanasios Zovoilis, associate professor of biochemistry and medical genetics in the Max Rady College of Medicine. “The right equipment for this new field of study has been in our lab for some time, but we lacked the tools to use it to its fullest potential, until now. The impact of employing AI and novel genomics approaches is that researchers across the world can now leverage next-generation sequencing in the new field of epitranscriptomics, exploring the genetic interactions of non-coding RNAs.”

“If we imagine the human genome as an atlas of the earth, with each gene represented by one satellite image, we have so far revealed fewer than 36,000 of the necessary 1.2 million images to complete our atlas. The mapped RNA sequences represent specific human tissues, and we are now able to begin filling in large sections of our atlas to pinpoint the genomic locations of diseases and other important biological functions for the first time,” Zovoilis added.

 

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.